1. Home
  2. LXRX vs CYH Comparison

LXRX vs CYH Comparison

Compare LXRX & CYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXRX
  • CYH
  • Stock Information
  • Founded
  • LXRX 1995
  • CYH 1985
  • Country
  • LXRX United States
  • CYH United States
  • Employees
  • LXRX N/A
  • CYH N/A
  • Industry
  • LXRX Biotechnology: Pharmaceutical Preparations
  • CYH Hospital/Nursing Management
  • Sector
  • LXRX Health Care
  • CYH Health Care
  • Exchange
  • LXRX Nasdaq
  • CYH Nasdaq
  • Market Cap
  • LXRX 690.5M
  • CYH N/A
  • IPO Year
  • LXRX 2000
  • CYH 1991
  • Fundamental
  • Price
  • LXRX $2.01
  • CYH $6.00
  • Analyst Decision
  • LXRX Buy
  • CYH Hold
  • Analyst Count
  • LXRX 2
  • CYH 5
  • Target Price
  • LXRX $10.00
  • CYH $5.07
  • AVG Volume (30 Days)
  • LXRX 2.5M
  • CYH 1.2M
  • Earning Date
  • LXRX 11-06-2024
  • CYH 10-23-2024
  • Dividend Yield
  • LXRX N/A
  • CYH N/A
  • EPS Growth
  • LXRX N/A
  • CYH N/A
  • EPS
  • LXRX N/A
  • CYH N/A
  • Revenue
  • LXRX $3,641,000.00
  • CYH $12,546,000,000.00
  • Revenue This Year
  • LXRX $1,288.95
  • CYH $1.83
  • Revenue Next Year
  • LXRX $276.56
  • CYH $4.17
  • P/E Ratio
  • LXRX N/A
  • CYH N/A
  • Revenue Growth
  • LXRX 794.59
  • CYH 1.26
  • 52 Week Low
  • LXRX $0.92
  • CYH $2.01
  • 52 Week High
  • LXRX $3.73
  • CYH $6.29
  • Technical
  • Relative Strength Index (RSI)
  • LXRX 73.60
  • CYH 60.98
  • Support Level
  • LXRX $1.60
  • CYH $5.15
  • Resistance Level
  • LXRX $1.84
  • CYH $6.01
  • Average True Range (ATR)
  • LXRX 0.10
  • CYH 0.28
  • MACD
  • LXRX 0.04
  • CYH 0.01
  • Stochastic Oscillator
  • LXRX 81.97
  • CYH 80.95

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Share on Social Networks: